Tenon Medical Statistics
Total Valuation
Tenon Medical has a market cap or net worth of $7.80 million. The enterprise value is $8.07 million.
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Tenon Medical has 11.30 million shares outstanding. The number of shares has increased by 359.57% in one year.
| Current Share Class | 11.30M |
| Shares Outstanding | 11.30M |
| Shares Change (YoY) | +359.57% |
| Shares Change (QoQ) | +15.06% |
| Owned by Insiders (%) | 7.03% |
| Owned by Institutions (%) | 3.92% |
| Float | 10.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.70 |
| Forward PS | 1.50 |
| PB Ratio | 4.11 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 2.57.
| Current Ratio | 1.03 |
| Quick Ratio | 0.89 |
| Debt / Equity | 2.57 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -66.00 |
Financial Efficiency
Return on equity (ROE) is -220.32% and return on invested capital (ROIC) is -87.96%.
| Return on Equity (ROE) | -220.32% |
| Return on Assets (ROA) | -55.35% |
| Return on Invested Capital (ROIC) | -87.96% |
| Return on Capital Employed (ROCE) | -213.80% |
| Weighted Average Cost of Capital (WACC) | 8.05% |
| Revenue Per Employee | $176,808 |
| Profits Per Employee | -$477,538 |
| Employee Count | 26 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 2.29 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.25% in the last 52 weeks. The beta is 1.28, so Tenon Medical's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -37.25% |
| 50-Day Moving Average | 0.75 |
| 200-Day Moving Average | 1.00 |
| Relative Strength Index (RSI) | 39.91 |
| Average Volume (20 Days) | 78,211 |
Short Selling Information
The latest short interest is 176,641, so 1.56% of the outstanding shares have been sold short.
| Short Interest | 176,641 |
| Short Previous Month | 193,192 |
| Short % of Shares Out | 1.56% |
| Short % of Float | 1.76% |
| Short Ratio (days to cover) | 2.28 |
Income Statement
In the last 12 months, Tenon Medical had revenue of $4.60 million and -$12.42 million in losses. Loss per share was -$1.33.
| Revenue | 4.60M |
| Gross Profit | 2.98M |
| Operating Income | -11.62M |
| Pretax Income | -12.42M |
| Net Income | -12.42M |
| EBITDA | -11.34M |
| EBIT | -11.62M |
| Loss Per Share | -$1.33 |
Full Income StatementBalance Sheet
The company has $4.61 million in cash and $4.88 million in debt, with a net cash position of -$270,000 or -$0.02 per share.
| Cash & Cash Equivalents | 4.61M |
| Total Debt | 4.88M |
| Net Cash | -270,000 |
| Net Cash Per Share | -$0.02 |
| Equity (Book Value) | 1.90M |
| Book Value Per Share | -0.10 |
| Working Capital | 215,000 |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 279,250 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 64.82%, with operating and profit margins of -252.69% and -270.09%.
| Gross Margin | 64.82% |
| Operating Margin | -252.69% |
| Pretax Margin | -270.09% |
| Profit Margin | -270.09% |
| EBITDA Margin | -246.61% |
| EBIT Margin | -252.69% |
| FCF Margin | n/a |
Dividends & Yields
Tenon Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -359.57% |
| Shareholder Yield | -359.57% |
| Earnings Yield | -159.25% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for Tenon Medical is $2.63, which is 281.05% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.63 |
| Price Target Difference | 281.05% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 60.85% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 6, 2024. It was a reverse split with a ratio of 1:8.
| Last Split Date | Sep 6, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
